<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: accumulated deficit", fill: "#ffb6c1"},
{source: "1: accumulated deficit", target: "1: approximately", fill: "#ffb6c1"},
{source: "1: approximately", target: "1: December ", fill: "#ffb6c1"},
{source: "1: accumulated deficit", target: "9: profitability", fill: "#cc4e5c"},
{source: "9: profitability", target: "9: increase profitability on", fill: "#cc4e5c"},
{source: "9: increase profitability on", target: "9: annual basis", fill: "#cc4e5c"},
{source: "9: profitability", target: "11: bioassay testing devices typically involves", fill: "#006994"},
{source: "11: bioassay testing devices typically involves", target: "11: significant", fill: "#006994"},
{source: "11: significant", target: "11: technical evaluation", fill: "#006994"},
{source: "11: technical evaluation", target: "11: commitment", fill: "#006994"},
{source: "11: commitment", target: "11: capital by partners", fill: "#006994"},
{source: "11: bioassay testing devices typically involves", target: "16: partners typically purchase instruments", fill: "#efdecd"},
{source: "16: partners typically purchase instruments", target: "16: instruments", fill: "#efdecd"},
{source: "16: instruments", target: "16: three phases during", fill: "#efdecd"},
{source: "16: three phases during", target: "16: commercialization cycle first instruments necessary", fill: "#efdecd"},
{source: "16: commercialization cycle first instruments necessary", target: "16: development", fill: "#efdecd"},
{source: "16: development", target: "16: demonstrations", fill: "#efdecd"},
{source: "16: demonstrations", target: "16: finally instruments", fill: "#efdecd"},
{source: "16: partners typically purchase instruments", target: "23: largely on", fill: "#8f00ff"},
{source: "23: largely on", target: "23: establishment", fill: "#8f00ff"},
{source: "23: establishment", target: "23: successful relationships with", fill: "#8f00ff"},
{source: "23: successful relationships with", target: "23: strategic partners", fill: "#8f00ff"},
{source: "23: largely on", target: "27: Furthermore ", fill: "#848482"},
{source: "27: Furthermore ", target: "27: December ", fill: "#848482"},
{source: "27: December ", target: "27: Companys ", fill: "#848482"},
{source: "27: Companys ", target: "27: total revenue", fill: "#848482"},
{source: "27: Furthermore ", target: "37: on convincing them", fill: "#f4c430"},
{source: "37: on convincing them", target: "37: technology", fill: "#f4c430"},
{source: "37: technology", target: "37: accelerate", fill: "#f4c430"},
{source: "37: on convincing them", target: "START_HERE", fill: "#f4c430"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Council_of_the_Baltic_Sea_States">Council of the Baltic Sea States</a></td>
      <td>The Council of the Baltic Sea States (CBSS) is a regional intergovernmental organisation working on three priority areas: Regional Identity, Safe &amp; Secure Region and Sustainable &amp; Prosperous Region. These three priority areas aim to address the themes of sustainable development, environment, sustainable maritime economy, education, labour, culture, youth engagement, civil security, children's rights and trafficking in human beings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strategic_alliance">Strategic alliance</a></td>
      <td>A strategic alliance (also see strategic partnership) is an agreement between two or more parties to pursue a set of agreed upon objectives needed while remaining independent organizations.\nThe alliance is a cooperation or collaboration which aims for a synergy where each partner hopes that the benefits from the alliance will be greater than those from individual efforts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Foreign_relations_of_India">Foreign relations of India</a></td>
      <td>India has diplomatic relations with 201 states/dependencies around the globe,  having 199 missions and posts operating globally while plans to open new missions in 2020-21 hosted by 11 UN Member States.\nThe Ministry of External Affairs (MEA), also known as the Foreign Ministry, is the government agency responsible for the conduct of foreign relations of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Total_revenue_share">Total revenue share</a></td>
      <td>The total revenue share is the percentage of direct cost associated with revenue. Direct cost consists of both product cost and marketing cost.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Marginal_revenue">Marginal revenue</a></td>
      <td>Marginal revenue (or marginal benefit) is a central concept in microeconomics that describes the additional total revenue generated by increasing product sales by 1 unit. To derive the value of marginal revenue, it is required to examine the difference between the aggregate benefits a firm received from the quantity of a good and service produced last period and the current period with one extra unit increase in the rate of production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Deloitte_Football_Money_League">Deloitte Football Money League</a></td>
      <td>The Deloitte Football Money League is a ranking of football clubs by revenue generated from football operations. It is produced annually by the accountancy firm Deloitte and released in early February of each year, describing the season most recently finished.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monopoly">Monopoly</a></td>
      <td>A monopoly (from Greek μόνος, mónos, 'single, alone' and πωλεῖν, pōleîn, 'to sell'), as described by Irving Fisher, is a market with the "absence of competition", creating a situation where a specific person or enterprise is the only supplier of a particular thing. This contrasts with a monopsony which relates to a single entity's control of a market to purchase a good or service, and with oligopoly and duopoly which consists of a few sellers dominating a market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tax_revenue">Tax revenue</a></td>
      <td>Tax revenue is the income that is collected by governments through taxation. Taxation is the primary source of government revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_management">Technology management</a></td>
      <td>Technology management is a set of management disciplines that allows organizations to manage their technological fundamentals to create customer advantage. Typical concepts used in technology management are:\n\nTechnology strategy (a logic or role of technology in organization),\nTechnology forecasting (identification of possible relevant technologies for the organization, possibly through technology scouting),\nTechnology roadmap (mapping technologies to business and market needs), and\nTechnology project portfolio (a set of projects under development) and technology portfolio (a set of technologies in use).The role of the technology management function in an organization is to understand the value of certain technology for the organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>LUMINEX CORP      ITEM 1A RISK FACTORS     We have a history of losses and an <font color="blue"><font color="blue">accumulated</font> deficit</font> of <font color="blue">approximately</font>     dlra86dtta6 million as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We have incurred <font color="blue">significant</font> net losses since our inception, including     losses of dlra2dtta7 million for the year ended <font color="blue">December </font>31, 2005, dlra3dtta6 million in     2004 and dlra4dtta2 million in 2003</td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated</font>     deficit of <font color="blue">approximately</font> dlra86dtta6 million</td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">profitability</font>, we need to     generate and <font color="blue">sustain <font color="blue">substantially</font> higher revenue while</font> achieving reasonable     cost and <font color="blue">expense levels</font></td>
    </tr>
    <tr>
      <td>If we fail to achieve <font color="blue">profitability</font> within the time     frame expected <font color="blue">by securities analysts</font> or investors, the <font color="blue">market price</font> of our     <font color="blue"><font color="blue">common stock</font> <font color="blue">will likely</font> decline</font></td>
    </tr>
    <tr>
      <td>Furthermore, as we continue to incur     losses and <font color="blue">utilize cash</font> to <font color="blue">support <font color="blue">operations</font></font>, we <font color="blue">may further decrease</font> the     cash  available  to  the  Company</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, cash, cash     <font color="blue">equivalents</font> and short-term and long-term investments totaled dlra41dtta6 million,     an  increase  of dlra5dtta5 million from dlra36dtta1 million at <font color="blue">December </font>31, 2004,     <font color="blue">primarily attributable</font> to more <font color="blue">efficient <font color="blue">management</font></font> of our <font color="blue">inventory levels</font>     and receipt of <font color="blue"><font color="blue">significant</font> license fees</font></td>
    </tr>
    <tr>
      <td>We do not know when or if we will     <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>If we do achieve <font color="blue">profitability</font>, we may not be able to     sustain or increase <font color="blue">profitability</font> on a quarterly or an <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>We expect our operating results to continue to <font color="blue">fluctuate from quarter</font> to     quarter</td>
    </tr>
    <tr>
      <td>The sale of <font color="blue">bioassay testing devices typically involves</font> a <font color="blue">significant</font>     <font color="blue">technical evaluation</font> and <font color="blue">commitment</font> of <font color="blue">capital by partners</font></td>
    </tr>
    <tr>
      <td>Accordingly, the     sales cycle associated with our products typically is lengthy and subject to     a number of <font color="blue">significant</font> risks, including partners’ <font color="blue">budgetary</font> <font color="blue">constraints</font>,     inventory <font color="blue">management</font> practices, <font color="blue">regulatory</font> approval and internal <font color="blue">acceptance</font>     reviews, all of which are beyond our control</td>
    </tr>
    <tr>
      <td>As a result of this lengthy     and unpredictable sales cycle, our operating results have <font color="blue">historically</font>     fluctuated <font color="blue">significant</font>ly from quarter to quarter</td>
    </tr>
    <tr>
      <td>We expect this trend to     continue for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The  vast  majority of our <font color="blue">system sales</font> are made to our strategic     partners</td>
    </tr>
    <tr>
      <td>Our <font color="blue">partners typically purchase <font color="blue">instruments</font></font> in <font color="blue">three phases during</font>     their <font color="blue">commercialization</font> cycle: first, <font color="blue">instruments</font> <font color="blue">necessary</font> to support     internal  assay  <font color="blue">development</font>;  second,  <font color="blue">instruments</font>  for  sales  force     <font color="blue">demonstrations</font>; and finally, <font color="blue">instruments</font> for resale to their customers</td>
    </tr>
    <tr>
      <td>As a     result,  most  of  our  system  <font color="blue">placements</font> are highly <font color="blue">dependent</font> on the     <font color="blue">commercialization</font> timetables of our <font color="blue">strategic partners</font> and can fluctuate     from quarter to quarter as our <font color="blue">strategic partners</font> move from phase to phase</td>
    </tr>
    <tr>
      <td>We expect this trend to continue for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Because of the effect of <font color="blue">bulk purchases</font>, we continue to experience     <font color="blue">fluctuations</font> in the percentage of our <font color="blue">quarterly revenues derived from</font> our     highest margin items, <font color="blue">consumables</font> and royalties</td>
    </tr>
    <tr>
      <td>Our gross margin is highly     <font color="blue">dependent</font>  upon  the  mix  of  revenue  <font color="blue"><font color="blue">components</font> each quarter</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">fluctuations</font> contribute to the <font color="blue">variability</font> and lack of <font color="blue">predictability</font> of     both gross <font color="blue">margin percentage</font> and total gross <font color="blue">profit from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>Our  success  depends  <font color="blue">largely on</font> the <font color="blue">establishment</font> and maintenance of     <font color="blue">successful <font color="blue">relationships</font> with</font> our <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>Currently, a limited     number of <font color="blue">strategic partners</font> <font color="blue">constitute</font> a majority of our revenue and the     loss of any one of these <font color="blue">partners could</font> have a material adverse effect on     the Company</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">xMAP <font color="blue">technology</font></font> is highly     <font color="blue">dependent</font> on our ability to <font color="blue">establish successful strategic <font color="blue">relationships</font></font>     with a number of partners</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had 24 strategic     partners who were <font color="blue">paying royalties</font> and had <font color="blue">either commercialized products</font>     using the Luminex platform or were reselling                                         12       _________________________________________________________________    [48]Table of <font color="blue">Contents       </font>our  products</td>
    </tr>
    <tr>
      <td>Furthermore, for the year ended <font color="blue">December </font>31, 2005, two     partners <font color="blue">individually represented</font> greater than 10prca of the Company’s revenue     and <font color="blue">collectively</font> represented 39prca of <font color="blue">total revenue</font> (Bio-Rad Laboratories,     Inc</td>
    </tr>
    <tr>
      <td>– 23prca; One Lambda, Inc</td>
    </tr>
    <tr>
      <td>We had <font color="blue">three <font color="blue">additional</font> partners</font> who     <font color="blue">individually represented</font> 5prca or more of our <font color="blue">total revenue</font> and <font color="blue">collectively</font>     represented 18prca of the Company’s revenue for the year ended <font color="blue">December </font>31,     2005</td>
    </tr>
    <tr>
      <td>In total, for the year ended <font color="blue">December </font>31, 2005, we had <font color="blue">five partners</font>     who represented 57prca of our <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">comparative purposes</font> for the     year ended <font color="blue">December </font>31, 2004, two partners <font color="blue">individually represented</font> greater     than 10prca of the Company’s revenue and <font color="blue">collectively</font> represented 35prca of our     <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>We had <font color="blue">two <font color="blue">additional</font> partners</font> who <font color="blue">individually represented</font>     5prca or more of our <font color="blue">total revenue</font> and <font color="blue">collectively</font> represented 10prca of the     Company’s revenue for the year ended <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>In total, for the     year ended <font color="blue">December </font>31, 2004, we had <font color="blue">four partners</font> who represented 45prca of     our <font color="blue">total revenue</font></td>
    </tr>
    <tr>
      <td>The loss of any of our <font color="blue">significant</font> <font color="blue">strategic partners</font>, or     any of our <font color="blue">significant</font> customers, could have a material adverse effect on     our growth and future results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Delays in <font color="blue">implementation</font>,     delays  in  obtaining  <font color="blue">regulatory</font> approval, changes in strategy or the     <font color="blue">financial <font color="blue">difficult</font>y</font> of our <font color="blue">strategic partners</font> for any <font color="blue">reason could</font> have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to enter into <font color="blue">agreements</font> with <font color="blue">additional</font> <font color="blue">strategic partners</font>     depends in part <font color="blue">on convincing them</font> that our <font color="blue">technology</font> can help achieve and     <font color="blue">accelerate</font> their goals or efforts</td>
    </tr>
    <tr>
      <td>We will expend substantial funds and     <font color="blue">management</font>  efforts  with  no  assurance that any <font color="blue"><font color="blue">additional</font> strategic</font>     <font color="blue"><font color="blue">relationships</font> will</font> result</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to     negotiate <font color="blue"><font color="blue">additional</font> strategic</font> <font color="blue">agreements</font> in the future on acceptable terms,     if at all, or that current or future <font color="blue">strategic partners</font> will not pursue or     develop <font color="blue">alternative <font color="blue">technologies</font> either on</font> their own or in <font color="blue">collaboration</font>     <font color="blue">with others</font></td>
    </tr>
    <tr>
      <td>Some of the companies we are targeting as <font color="blue">strategic partners</font>     <font color="blue">offer products <font color="blue">competitive</font> with</font> our <font color="blue">xMAP <font color="blue">technology</font></font>, which may hinder or     <font color="blue">prevent strategic <font color="blue">relationships</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of strategic <font color="blue">relationships</font>, or     the failure to enter into a sufficient number of <font color="blue">additional</font> <font color="blue">agreements</font> on     favorable terms, <font color="blue">could reduce</font> sales of our products, <font color="blue">lower margins</font> on our     products and limit the creation of market demand and <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>In addition, we have entered into non-exclusive <font color="blue">relationships</font> with most     of our existing <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>The lack of <font color="blue">exclusivity could deter</font>     existing <font color="blue">strategic partners</font> from commercializing <font color="blue">xMAP <font color="blue">technology</font></font> and may     deter new <font color="blue">strategic partners</font> from entering into <font color="blue">agreements</font> with Luminex</td>
    </tr>
    <tr>
      <td>The majority of our <font color="blue">future revenues will come from sales</font> of our systems     and the <font color="blue">development</font> and sale of <font color="blue">bioassay kits utilizing</font> our <font color="blue">technology</font> by     our <font color="blue">strategic partners</font> and from use of our <font color="blue">technology</font> by our strategic     partners in performing <font color="blue">services offered</font> to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We believe that     our <font color="blue">strategic partners</font> will have <font color="blue">economic <font color="blue">incentives</font></font> to develop and market     these products, but we <font color="blue">cannot predict future sales</font> and <font color="blue">royalty revenues</font>     because most of our existing strategic partner <font color="blue">agreements</font> do not include     <font color="blue">minimum purchase <font color="blue">requirements</font></font> or royalty <font color="blue">commitment</font>s</td>
    </tr>
    <tr>
      <td>In addition, we do not     have the right or ability to <font color="blue">provide <font color="blue">incentives</font></font> to our <font color="blue">strategic partners</font>’     <font color="blue">sales personnel</font> to sell products <font color="blue">based on</font> <font color="blue">xMAP <font color="blue">technology</font></font> or to control the     timing of the release of <font color="blue">products by</font> our <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>The amount of     these <font color="blue">revenues will <font color="blue">depend on</font></font> a variety of factors that are outside our     control, including the amount and timing of resources that current and     future  strategic  partners  devote  to  develop  and  <font color="blue">market products</font>     <font color="blue">incorporating</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Further, the <font color="blue">development</font> and marketing of     certain  bioassay  kits  will require our <font color="blue">strategic partners</font> to obtain     <font color="blue">governmental</font> approvals, <font color="blue">which could</font> delay or prevent their <font color="blue">commercialization</font>     efforts</td>
    </tr>
    <tr>
      <td>If our current or future <font color="blue">strategic partners</font> do not <font color="blue">successfully</font>     develop and <font color="blue">market products</font> <font color="blue">based on</font> our <font color="blue">technology</font> and obtain <font color="blue">necessary</font>     <font color="blue">government approvals</font>, our <font color="blue">revenues from product sales</font> and <font color="blue">royalties will</font> be     <font color="blue">significant</font>ly reduced</td>
    </tr>
    <tr>
      <td>If  our  <font color="blue">technology</font> and products do not <font color="blue">become widely used</font> in the life     <font color="blue">sciences industry</font>, it is unlikely that we will ever <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Life <font color="blue">sciences companies</font> have <font color="blue">historically</font> conducted biological tests     using a variety of <font color="blue">technologies</font>, including bead-based analysis</td>
    </tr>
    <tr>
      <td>Our xMAP     <font color="blue">technology</font> is <font color="blue">relatively new</font> and unproven, in <font color="blue">certain testing areas</font>, and the     use of our <font color="blue">technology</font> by life <font color="blue">sciences companies</font> is limited</td>
    </tr>
    <tr>
      <td>The commercial     success of our <font color="blue">technology</font> will depend upon its <font color="blue">widespread adoption as</font> a     method to perform <font color="blue">bioassays</font></td>
    </tr>
    <tr>
      <td>In order to be successful, we <font color="blue">must convince</font>     <font color="blue">potential partners</font> to utilize our <font color="blue">system instead</font> of competing <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> will <font color="blue">depend on</font> many factors, including our ability to:                                         13       _________________________________________________________________    [49]Table of <font color="blue">Contents       </font>–   convince prospective <font color="blue">strategic partners</font> and customers that our     <font color="blue">technology</font> is an <font color="blue">attractive alternative</font> to other <font color="blue">technologies</font> for     <font color="blue">pharmaceutical</font>, research, clinical and <font color="blue">biomedical testing</font> and analysis;       –    encourage these partners to develop and <font color="blue">market products</font> using our     <font color="blue">technology</font>;       –   <font color="blue">manufacture products</font> in <font color="blue"><font color="blue">sufficient quantities</font> with</font> acceptable quality     and at an acceptable cost;       –   obtain and maintain <font color="blue">sufficient pricing</font> and <font color="blue">royalties from partners on</font>     such Luminex products; and       –   place and service <font color="blue">sufficient quantities</font> of our products, including the     ability to provide the level of service required in the <font color="blue">mainstream clinical</font>     <font color="blue"><font color="blue">diagnostic</font>s market</font> segment</td>
    </tr>
    <tr>
      <td>Because of these and other factors, our <font color="blue">products may</font> not <font color="blue">gain sufficient</font>     market <font color="blue">acceptance</font> to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> <font color="blue">strategic partners</font> to market our products makes <font color="blue">forecasting</font>     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td><font color="blue">Primarily </font>as a result of our <font color="blue"><font color="blue">reliance on</font> partner performance</font>, it is     <font color="blue">difficult</font> to <font color="blue"><font color="blue">accurately</font> forecast future</font> operating results</td>
    </tr>
    <tr>
      <td>Our operating     expenses  are  <font color="blue">largely <font color="blue">based on</font></font> anticipated <font color="blue">revenue trends</font>, and a high     percentage  of our expenses are, and <font color="blue">will continue</font> to be, fixed in the     short-term</td>
    </tr>
    <tr>
      <td>The level of our <font color="blue">revenues will depend upon</font> the rate and timing     of the adoption of our <font color="blue">technology</font> as a method to perform <font color="blue">bioassays</font></td>
    </tr>
    <tr>
      <td>Due to     our limited operating history, predicting this timing and rate of adoption     is <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>In addition, we currently anticipate that the vast majority of future     sales of our products and products <font color="blue">incorporating</font> our <font color="blue">technology</font> will be made     by our <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>For the following reasons, estimating the timing     and amount of sales of these products that may be made by our strategic     partners is <font color="blue">particularly</font> <font color="blue">difficult</font>:     –   We have <font color="blue">no control over</font> the timing or extent of product <font color="blue">development</font>,     marketing or sale of our <font color="blue">products by</font> our <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>–   Most of our <font color="blue">strategic partners</font> are not committed to minimum purchase     <font color="blue">commitment</font>s, and we do not control the <font color="blue">incentives</font> provided by our strategic     partners to their <font color="blue">sales personnel</font></td>
    </tr>
    <tr>
      <td>–     A <font color="blue">significant</font> number of our <font color="blue">strategic partners</font> intend to produce     <font color="blue">clinical <font color="blue">diagnostic</font> <font color="blue">applications</font></font> that may need to be <font color="blue">approved by</font> the Food     and Drug Administration, or other <font color="blue">regulatory</font> bodies in <font color="blue"><font color="blue"><font color="blue">jurisdiction</font>s</font> outside</font>     of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>–    Certain <font color="blue">strategic partners</font> may have <font color="blue">unique <font color="blue">requirements</font></font> for their     <font color="blue">applications</font> and systems</td>
    </tr>
    <tr>
      <td><font color="blue">Assisting </font>the various <font color="blue">strategic partners</font> may     strain our research and <font color="blue">development</font> and <font color="blue">manufacturing</font> resources</td>
    </tr>
    <tr>
      <td>To the     extent that we are not able to timely assist our <font color="blue">strategic partners</font>, the     <font color="blue">commercialization</font> of their products <font color="blue">will likely</font> be delayed</td>
    </tr>
    <tr>
      <td>–   Certain <font color="blue">strategic partners</font> may fail to deliver products that satisfy     <font color="blue">market <font color="blue">requirements</font></font>, or such <font color="blue">products may</font> fail to perform properly</td>
    </tr>
    <tr>
      <td>–   We have limited access to <font color="blue">partner <font color="blue">confidential</font> corporate</font> information</td>
    </tr>
    <tr>
      <td>A     <font color="blue">sudden unexpected</font> change in ownership, strategy or other material event     <font color="blue">could adversely impact partner purchases</font> of our products</td>
    </tr>
    <tr>
      <td>The  life <font color="blue">sciences industry</font> is <font color="blue">highly <font color="blue">competitive</font></font> and subject to rapid     <font color="blue">technological</font> change and we may not have the resources <font color="blue">necessary</font> to compete     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with companies</font> in the <font color="blue">United States</font> and abroad that are     engaged in the <font color="blue">development</font> and production of similar products</td>
    </tr>
    <tr>
      <td>We will     continue to <font color="blue">face intense <font color="blue">competition</font> from existing <font color="blue">competitors</font></font> and other     <font color="blue">companies seeking</font> to develop new <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have     access to greater financial, technical, scientific, research, marketing,     sales, <font color="blue">distribution</font>, service and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>These companies     may develop <font color="blue">technologies</font> that are superior <font color="blue">alternatives</font> to our <font color="blue">technologies</font>     or may be more <font color="blue">effective at commercializing</font> their <font color="blue">technologies</font> in products</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [50]Table of <font color="blue">Contents       </font>     The life <font color="blue">sciences industry</font> is <font color="blue">characterized by rapid</font> and <font color="blue">continuous</font>     <font color="blue">technological</font> innovation</td>
    </tr>
    <tr>
      <td>We may need to develop new <font color="blue">technologies</font> for our     products  to  <font color="blue">remain <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>One or more of our current or future     <font color="blue">competitors</font>  could  render  our present or future products obsolete or     uneconomical by <font color="blue">technological</font> advances</td>
    </tr>
    <tr>
      <td>In addition, the introduction or     <font color="blue">announcement</font> of new <font color="blue">products by</font> us or <font color="blue">others could</font> result in a delay of or     decrease in sales of existing products, as we await <font color="blue">regulatory</font> approvals and     as  <font color="blue">customers evaluate</font> these <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We may also encounter other     problems in the process of delivering <font color="blue">new products</font> to the marketplace,     including <font color="blue">products from</font> our Biosciences Group, <font color="blue">such as problems</font> related to     design, <font color="blue">development</font> or <font color="blue">manufacturing</font> of <font color="blue">such products</font>, and as result we may     be <font color="blue">unsuccessful</font> in selling <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">success will depend</font> on</font>     our ability to compete <font color="blue">effectively</font> against current <font color="blue">technologies</font>, as well as     to respond <font color="blue">effectively</font> to <font color="blue">technological</font> advances by developing and marketing     products that are <font color="blue">competitive</font> in the <font color="blue">continually</font> changing <font color="blue">technological</font>     landscape</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to service and support our products     directly or in <font color="blue">collaboration</font> with our <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>To  the extent that <font color="blue">the Company </font>or its <font color="blue">strategic partners</font> fail to     maintain a high quality level of service and support for <font color="blue">xMAP <font color="blue">technology</font></font>     products, there is a risk that the perceived quality of our <font color="blue">xMAP <font color="blue">technology</font></font>     products will be diminished in the marketplace</td>
    </tr>
    <tr>
      <td>Likewise, <font color="blue">the Company </font>may     fail to provide the level, quantity or quality, of service expected by the     marketplace</td>
    </tr>
    <tr>
      <td>This could result in <font color="blue">slower adoption rates</font> and lower than     anticipated <font color="blue">utilization</font> of xMAP products causing a material <font color="blue">adverse affect</font>     on our business</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">intellectual property</font> rights</font> we rely upon to protect the <font color="blue">technology</font>     underlying our <font color="blue">products may</font> not be adequate to maintain <font color="blue">market exclusivity</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inadequate </font><font color="blue">intellectual property</font> protection could enable <font color="blue">third parties</font> to     exploit our <font color="blue">technology</font> or use very similar <font color="blue">technology</font> and <font color="blue">could reduce</font> our     ability to distinguish our products in the market</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, on our ability to obtain, protect and     <font color="blue">enforce patents on</font> our <font color="blue">technology</font> and to protect our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Any     patents  we  own may not afford full protection for our <font color="blue">technology</font> and     products</td>
    </tr>
    <tr>
      <td>Others <font color="blue">may challenge</font> our patents and, as a result, our patents     could be narrowed or invalidated</td>
    </tr>
    <tr>
      <td>In addition, our current and <font color="blue">future patent</font>     <font color="blue">applications</font> may not result in the issuance of patents in the <font color="blue">United States</font>     or foreign countries</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may develop products that are not covered     by  our  patents</td>
    </tr>
    <tr>
      <td>Further,  there  is a substantial backlog of patent     <font color="blue">applications</font> at the US Patent and Trademark Office, and the approval or     rejection of patent <font color="blue">applications</font> may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We  have  obtained  32  patents  in the <font color="blue">United States</font> and foreign     <font color="blue"><font color="blue">jurisdiction</font>s</font>  directed  to  various  aspects  and <font color="blue">applications</font> of our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have 62 pending <font color="blue">applications</font> in the <font color="blue">United States</font> and foreign     <font color="blue"><font color="blue">jurisdiction</font>s</font></td>
    </tr>
    <tr>
      <td>In Japan, due to a <font color="blue">procedural omission</font>, we are unable to     obtain  patent  protection for our method of “real time” <font color="blue">detection</font> and     <font color="blue">quantification</font> of <font color="blue">multiple analytes from</font> a single sample similar to the     protection we have obtained in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Although we are pursuing     <font color="blue">patent protection</font> in Japan for other aspects of our <font color="blue">technology</font>, we may not     be able to prevent <font color="blue">competitors</font> from developing and marketing <font color="blue">technologies</font>     similar to our <font color="blue">xMAP <font color="blue">technology</font></font> in Japan</td>
    </tr>
    <tr>
      <td>We require our employees, consultants, <font color="blue">strategic partners</font> and other     <font color="blue">third parties</font> to execute <font color="blue">confidential</font>ity <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Our employees and     third-party consultants also sign <font color="blue">agreements</font> requiring that they assign to     us  their  interests  in  <font color="blue">inventions</font>  and <font color="blue">original expressions</font> and any     <font color="blue">corresponding patents</font> and <font color="blue">copyrights</font> arising from their work for us</td>
    </tr>
    <tr>
      <td>In     addition,  <font color="blue">the Company </font>has implemented a <font color="blue">patent process</font> to <font color="blue">file patent</font>     <font color="blue">applications</font> on its key <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot guarantee</font> that these     <font color="blue">agreements</font> or this <font color="blue">patent process</font> will <font color="blue">provide us with adequate</font> protection     against  improper  use  of  our <font color="blue">intellectual property</font> or <font color="blue">disclosure</font> of     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>In addition, in some situations, these <font color="blue">agreements</font>     <font color="blue">may conflict with</font>, or be subject to, the rights of <font color="blue">third parties</font> with whom     our employees, consultants or advisors have <font color="blue">prior employment</font> or consulting     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>Further, others may in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font>     equivalent <font color="blue">proprietary</font> <font color="blue">technology</font> and <font color="blue">techniques</font>, or <font color="blue">otherwise gain access</font>     to our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Our failure to protect our <font color="blue">proprietary</font> information and     <font color="blue">techniques</font> may inhibit or limit our ability to exclude certain <font color="blue">competitors</font>     from the market</td>
    </tr>
    <tr>
      <td>In  order to protect or enforce our <font color="blue">patent rights</font>, we may have to     initiate legal <font color="blue">proceedings</font> against <font color="blue">third parties</font>, such as infringement suits     or <font color="blue">interference <font color="blue">proceedings</font></font></td>
    </tr>
    <tr>
      <td>These <font color="blue">legal <font color="blue">proceedings</font> could</font> be expensive,     take <font color="blue">significant</font>                                         15       _________________________________________________________________    [51]Table of <font color="blue">Contents       </font>time and/or divert <font color="blue">management</font>’s attention from other business concerns</td>
    </tr>
    <tr>
      <td>These  <font color="blue">proceedings</font>  may  cause  us  to lose the benefit of some of our     <font color="blue"><font color="blue">intellectual property</font> rights</font>, the loss of <font color="blue">which may inhibit</font> or preclude our     ability to exclude certain <font color="blue">competitors</font> from the market</td>
    </tr>
    <tr>
      <td>We <font color="blue">also may provoke</font>     these <font color="blue">third parties</font> to assert claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of     companies like <font color="blue">ours generally</font> is highly uncertain, involves complex legal     and factual questions and has <font color="blue">recently been</font> the subject of much <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent policy</font> has <font color="blue">emerged from</font> the <font color="blue">US Patent and Trademark Office </font>    or the courts regarding the breadth of claims allowed or the degree of     <font color="blue">protection afforded under patents</font> like ours</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> partly on our ability to operate <font color="blue">without infringing</font>     on or <font color="blue">misappropriating</font> the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>We may be sued for infringing the <font color="blue"><font color="blue">intellectual property</font> rights</font> of     others</td>
    </tr>
    <tr>
      <td>In addition, we may find it <font color="blue">necessary</font>, if threatened, to initiate a     <font color="blue">lawsuit seeking</font> a <font color="blue">declaration from</font> a court that we do not <font color="blue">infringe on</font> the     <font color="blue">proprietary</font>  rights  of  others  or  that  their rights are invalid or     unenforceable</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property <font color="blue">litigation</font> is costly, and, even if we     prevail,  the  cost of such <font color="blue">litigation</font> could affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">litigation</font> is time consuming and could divert <font color="blue">management</font>’s     attention and <font color="blue">resources away from</font> our business</td>
    </tr>
    <tr>
      <td>If we do not prevail in any     <font color="blue">litigation</font>, we may have to pay damages and could be required to stop the     <font color="blue">infringing activity</font> or obtain a license</td>
    </tr>
    <tr>
      <td>Any required <font color="blue">license may</font> not be     available to us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Moreover, some <font color="blue">licenses may</font>     be <font color="blue">nonexclusive</font>, and therefore, our <font color="blue">competitors</font> may have access to the same     <font color="blue">technology</font> licensed to us</td>
    </tr>
    <tr>
      <td>If we fail to obtain a required license or are     unable to <font color="blue">design around</font> a patent, we may be unable to sell some of our     products,  <font color="blue">which could</font> have a material <font color="blue">adverse affect</font> on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are aware of a European <font color="blue">patent granted</font> to Dr</td>
    </tr>
    <tr>
      <td>Ioannis Tripatzis,     which  <font color="blue">covers certain testing agents</font> and <font color="blue">certain methods</font> of their use</td>
    </tr>
    <tr>
      <td>Tripatzis has publicly stated his belief that his European <font color="blue">patent covers</font>     aspects of our <font color="blue">technology</font> if practiced in Europe</td>
    </tr>
    <tr>
      <td><font color="blue">This European </font>patent     expired in November 2004</td>
    </tr>
    <tr>
      <td>We  have  only  produced our products in limited quantities and we may     experience problems in scaling our <font color="blue">manufacturing</font> <font color="blue">operations</font> or delays or     component shortages that <font color="blue">could limit</font> the growth of our revenue</td>
    </tr>
    <tr>
      <td>To date, we have produced our products in limited <font color="blue">quantities compared</font>     to the quantities <font color="blue">necessary</font> to achieve desired <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>We may not be     able  to produce <font color="blue">sufficient quantities</font> or maintain <font color="blue">consistency between</font>     <font color="blue">differing lots</font> of <font color="blue">consumables</font></td>
    </tr>
    <tr>
      <td>If we encounter <font color="blue">difficult</font>ies in scaling our     <font color="blue">manufacturing</font> <font color="blue">operations</font> as a result of, among other things, quality control     and  quality  assurance and <font color="blue">availability</font> of component and raw material     supplies, we <font color="blue">will likely</font> experience <font color="blue">reduced sales</font> of our products, increased     repair  or re-engineering costs due to <font color="blue">product returns</font> and defects and     <font color="blue">increased expenses due</font> to switching to <font color="blue">alternate suppliers</font>, any of which     would reduce our revenues and gross margins</td>
    </tr>
    <tr>
      <td>We <font color="blue">presently outsource certain aspects</font> of the assembly of our systems     to <font color="blue">contract manufacturers</font></td>
    </tr>
    <tr>
      <td>Because of a long lead-time to delivery, we are     required to place orders for a variety of <font color="blue">items well</font> in advance of scheduled     <font color="blue">production runs</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">recently increased</font> our <font color="blue">flexibility</font> to <font color="blue">purchase strategic</font>     <font color="blue">components</font> within shorter lead times by entering into supply <font color="blue">agreements</font> with     the suppliers of these <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Although we attempt to match our parts     inventory and <font color="blue">production <font color="blue">capabilities</font></font> to estimates of <font color="blue">marketplace demand</font>, to     the  extent  system  <font color="blue">orders materially vary from</font> our estimates, we may     experience continued <font color="blue">constraints</font> in our <font color="blue">systems production</font> and delivery     capacity, <font color="blue">which could</font> adversely impact revenue in a <font color="blue">given fiscal period</font></td>
    </tr>
    <tr>
      <td>Should  the  Company’s  need  for <font color="blue">raw materials</font> and <font color="blue">components</font> used in     <font color="blue">production continue</font> to fluctuate, we could incur <font color="blue">additional</font> costs associated     <font color="blue">with either expediting</font> or <font color="blue">postponing delivery</font> of those materials</td>
    </tr>
    <tr>
      <td>In an     effort  to  control  costs  in  the last quarter of 2005 <font color="blue">manufacturing</font>     implemented a lean production system</td>
    </tr>
    <tr>
      <td>Managing the change from discrete to     <font color="blue">continuous</font>  flow  production  requires time and <font color="blue">management</font> <font color="blue">commitment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of lean initiatives and our supply chain <font color="blue">capabilities</font> may     result in part shortages that delay shipments and cause <font color="blue">fluctuations</font> in     revenue in a <font color="blue">given period</font></td>
    </tr>
    <tr>
      <td>Certain key <font color="blue">components</font> of our <font color="blue">product line</font> are <font color="blue">currently purchased from</font>     a limited number of <font color="blue">outside sources</font> and may only be <font color="blue">available through</font> a     limited number of providers</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">agreements</font> with all of our     suppliers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> our suppliers and <font color="blue">contract manufacturers</font> exposes     us to risks including:     –   the <font color="blue">possibility</font> that one or more of our suppliers or our <font color="blue">assemblers</font> that     do not have supply <font color="blue">agreements</font> with <font color="blue">the Company </font><font color="blue">could terminate</font> their     services at any time without penalty;                                         16       _________________________________________________________________    [52]Table of <font color="blue">Contents       </font>–   the potential obsolescence and/or <font color="blue">inability</font> of our suppliers to obtain     required <font color="blue">components</font>;       –   the potential delays and expenses of seeking alternate sources of supply     or <font color="blue">manufacturing</font> services;       –   the <font color="blue">inability</font> to qualify alternate sources without impacting performance     claims of our products;       –   reduced control over pricing, quality and timely delivery due to the     <font color="blue">difficult</font>ies in switching to <font color="blue">alternate suppliers</font> or <font color="blue">assemblers</font>; and       –   increases in prices of <font color="blue">raw materials</font> and key <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Consequently,  in  the  event that supplies of <font color="blue">components</font> or work     performed  by any of our <font color="blue">assemblers</font> are delayed or <font color="blue">interrupted</font> for any     reason, our ability to produce and supply our <font color="blue">products could</font> be impaired</td>
    </tr>
    <tr>
      <td>The <font color="blue">capital <font color="blue">spending policies</font></font> of our customers has a <font color="blue">significant</font> effect on     the demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">Customers    </font>include    clinical    <font color="blue">diagnostic</font>,   <font color="blue">pharmaceutical</font>,     bio<font color="blue">technological</font>,  chemical  and <font color="blue">industrial companies</font>, and the capital     <font color="blue">spending policies</font> of these companies can have a <font color="blue">significant</font> effect on the     demand for our products</td>
    </tr>
    <tr>
      <td>These policies are <font color="blue">based on</font> a wide variety of     factors, including <font color="blue">governmental</font> regulation or <font color="blue">price controls</font>, the resources     available for <font color="blue">purchasing research equipment</font>, the <font color="blue">spending priorities among</font>     <font color="blue">various types</font> of <font color="blue">analytical equipment</font> and the policies regarding capital     <font color="blue">expenditures during recessionary periods</font></td>
    </tr>
    <tr>
      <td>Any decrease in <font color="blue">capital spending</font>     by life <font color="blue">sciences companies</font> could cause our revenues to decline</td>
    </tr>
    <tr>
      <td>As a result,     we  are  subject  to <font color="blue">significant</font> <font color="blue">volatility</font> in revenue</td>
    </tr>
    <tr>
      <td>Therefore, our     operating results can be materially affected (negatively and positively) by     the <font color="blue">spending policies</font> and priorities of our customers</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">comply with</font> government <font color="blue">regulations</font></font> that affect our business,     we  could be subject to <font color="blue">enforcement action</font>s, <font color="blue">injunctions</font> and civil and     <font color="blue">criminal penalties</font> that <font color="blue">could delay</font> or <font color="blue">prevent marketing</font> of our products</td>
    </tr>
    <tr>
      <td>The production, testing, labeling, marketing and <font color="blue">distribution</font> of our     products for some purposes and products <font color="blue">based on</font> our <font color="blue">technology</font> are subject     to <font color="blue">governmental</font> regulation by the <font color="blue">United States</font> Food and Drug Administration     (FDA) and by similar agencies in other countries</td>
    </tr>
    <tr>
      <td>Some of our products and     products  <font color="blue">based on</font> our <font color="blue">technology</font> for in vitro <font color="blue">diagnostic</font> purposes are     subject  to  approval  or  <font color="blue">clearance by</font> the FDA prior to marketing for     <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>To date, 8 <font color="blue">strategic partners</font> have obtained <font color="blue">such approvals</font>     or <font color="blue">clearances</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">necessary</font>     FDA <font color="blue">clearances</font> or approvals can be time-consuming, expensive and uncertain</td>
    </tr>
    <tr>
      <td>Further, clearance or <font color="blue">approval may</font> place substantial <font color="blue">restrictions on</font> the     <font color="blue">indications</font> for which the <font color="blue">product may</font> be marketed or to whom it may be     marketed</td>
    </tr>
    <tr>
      <td>In addition, because some of our products employ laser <font color="blue">technology</font>,     we are also required to <font color="blue">comply with</font> FDA <font color="blue">requirements</font> relating to radiation     performance safety standards (21 CFR 1040dtta1 and 1040dtta11)</td>
    </tr>
    <tr>
      <td>Approved or cleared medical device products are subject to continuing     FDA <font color="blue">requirements</font> relating to, <font color="blue">among others</font>, <font color="blue">manufacturing</font> quality control     and  quality  assurance,  maintenance  of  records  and <font color="blue">documentation</font>,     <font color="blue">registration</font> and listing, import/export, adverse event and other reporting,     <font color="blue">distribution</font>, labeling and promotion and <font color="blue">advertising</font> of <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font>, or the <font color="blue">inability</font> of our <font color="blue">strategic partners</font>, to obtain required     <font color="blue">regulatory</font> approval or <font color="blue">clearance on</font> a timely or acceptable <font color="blue">basis could harm</font>     our business</td>
    </tr>
    <tr>
      <td>In addition, failure to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font>     <font color="blue">requirements</font>  could subject us or our <font color="blue">strategic partners</font> to <font color="blue">regulatory</font>     <font color="blue">enforcement action</font>, including warning letters, product seizures, recalls,     withdrawal  of <font color="blue">clearances</font> or approvals, <font color="blue">restrictions on</font> or <font color="blue">injunctions</font>     <font color="blue">against marketing</font> our products or products <font color="blue">based on</font> our <font color="blue">technology</font>, and     civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Medical  </font>device  laws  and <font color="blue">regulations</font> are also in effect in many     <font color="blue">countries outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">range from comprehensive</font> device     approval <font color="blue">requirements</font> for some or all of our medical device products to     requests  for  product  data or <font color="blue">certifications</font></td>
    </tr>
    <tr>
      <td>As part of the Council     <font color="blue">Directive </font>2002/96 of <font color="blue">February </font>13, 2003 (WEEE), we are expected to comply     with certain <font color="blue">requirements</font> regarding the labeling of our <font color="blue">products containing</font>     <font color="blue">electronic devices beginning on</font> August 13, 2005 in each of the EU member     states where our <font color="blue">regulated products</font> are <font color="blue">distributed</font></td>
    </tr>
    <tr>
      <td>While we are taking     steps to <font color="blue">comply with</font> the <font color="blue">requirements</font> of WEEE, we cannot be certain that we     will <font color="blue">comply with</font> the national stage <font color="blue">implementation</font> of WEEE in all member     states</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">currently exempt from</font> the <font color="blue">Council                                         </font>17       _________________________________________________________________    [53]Table of <font color="blue">Contents       </font><font color="blue">Directive </font>2002/95 of January 27, 2003, Restriction of Hazardous Substances     (RoHS), which requires the removal of <font color="blue">certain specified hazardous substances</font>     for <font color="blue">certain products beginning</font> July 1, 2006 in each of the member states</td>
    </tr>
    <tr>
      <td>However,  the European Union has indicated that it may include medical     devices, including some of our products, under the <font color="blue">jurisdiction</font> of <font color="blue">RoHS The     </font>number and scope of these <font color="blue">requirements</font> are increasing</td>
    </tr>
    <tr>
      <td>Failure to comply     with  applicable  federal,  state  and foreign medical device laws and     <font color="blue">regulations</font>  may harm our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are also subject to a variety of other laws and <font color="blue">regulations</font>     relating to, among other things, environmental protection and work place     safety</td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategic partners</font> and customers expect our <font color="blue">organization</font> to operate     on an established quality <font color="blue">management</font> system compliant with FDA Quality     System Regulations and <font color="blue">industry standards</font>, the In Vitro Diagnostic <font color="blue">Directive </font>    98/79/EC of 27 October 1998 (“Directive”) <font color="blue">as implemented nationally</font> in the     EU member states and <font color="blue">industry standards</font>, such as ISO 9000</td>
    </tr>
    <tr>
      <td>We became ISO     9001:2000 certified in March 2002 and self-declared our Luminex 100 and     Luminex 200 devices are in <font color="blue">conformity with</font> Article 1, Article 9, Annex I     (Essential Requirements), and Annex III, and the <font color="blue">additional</font> provisions of     IVDD 98/79/EC as of <font color="blue">December </font>7, 2003</td>
    </tr>
    <tr>
      <td><font color="blue">Subsequent </font>audits are carried out     annually to ensure we maintain our system in substantial <font color="blue">compliance with</font> ISO     and other applicable <font color="blue">regulations</font> and <font color="blue">industry standards</font></td>
    </tr>
    <tr>
      <td>Failure to maintain <font color="blue">compliance with</font> FDA,     CMDCAS  and EU <font color="blue">regulations</font> and other medical device laws, or to obtain     applicable  <font color="blue">registration</font>s where required, <font color="blue">could reduce</font> our <font color="blue">competitive</font>     advantage in the markets in which we compete and <font color="blue">also decrease satisfaction</font>     and <font color="blue">confidence levels with</font> our partners</td>
    </tr>
    <tr>
      <td>If we become subject to <font color="blue">product liability</font> claims, we may be required to pay     damages that exceed our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">exposes us</font> to potential <font color="blue">product liability</font> claims that are     inherent in the testing, production, marketing and sale of human <font color="blue">diagnostic</font>     and <font color="blue">therapeutic products</font></td>
    </tr>
    <tr>
      <td>Although we believe that we are <font color="blue">reasonably insured</font>     against  these risks and we have <font color="blue">indemnity protections</font> in our supplier     <font color="blue">agreements</font>,  there  can be no assurance that we will be able to obtain     insurance  in  amounts or <font color="blue">scope sufficient</font> to <font color="blue">provide us with adequate</font>     <font color="blue">coverage against</font> all <font color="blue">potential liabilities</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">product liability</font> claim in     excess of our <font color="blue">insurance coverage</font> or claim that is outside or exceeds our     <font color="blue">indemnity protections</font> in our supplier <font color="blue">agreements</font> or a recall of one of our     <font color="blue">products would</font> have to be paid out of our <font color="blue">cash reserves</font></td>
    </tr>
    <tr>
      <td>If third-party payors increasingly restrict payments for <font color="blue">healthcare expenses</font>     or fail to <font color="blue">adequately pay</font> for multi-analyte testing, we may experience     <font color="blue">reduced sales</font> which would hurt our business and our business prospects</td>
    </tr>
    <tr>
      <td>Third-party payors, such as government entities, health maintenance     <font color="blue">organization</font>s and <font color="blue">private insurers</font>, are <font color="blue">restricting payments</font> for healthcare</td>
    </tr>
    <tr>
      <td>These <font color="blue">restrictions may decrease demand</font> for our products and the price we can     charge</td>
    </tr>
    <tr>
      <td>Increasingly, Medicaid and other third-party payors are <font color="blue">challenging</font>     the <font color="blue">prices charged</font> for <font color="blue">medical services</font>, including clinical <font color="blue">diagnostic</font>     tests</td>
    </tr>
    <tr>
      <td>They are <font color="blue">also attempting</font> to <font color="blue">contain costs by limiting coverage</font> and     the <font color="blue">reimbursement level</font> of tests and other <font color="blue">healthcare products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Without     </font>adequate  coverage  and  reimbursement, consumer demand for tests will     decrease</td>
    </tr>
    <tr>
      <td><font color="blue">Decreased </font><font color="blue">demand could</font> cause sales of our products, and sales and     <font color="blue">services by</font> our <font color="blue">strategic partners</font>, to fall</td>
    </tr>
    <tr>
      <td>In addition, decreased demand     could place <font color="blue">pressure on us</font>, or our <font color="blue">strategic partners</font>, to <font color="blue">lower prices on</font>     these products or services, resulting in <font color="blue">lower margins</font></td>
    </tr>
    <tr>
      <td>Reduced sales or     margins  by  us,  or  our <font color="blue">strategic partners</font>, would hurt our business,     <font color="blue">profitability</font> and business prospects</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font> in <font color="blue">implementing</font> our <font color="blue"><font color="blue">acquisition</font> strategy</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions  </font>of  assets  or  entities designed to <font color="blue">accelerate</font> the     <font color="blue">implementation</font>  of  our strategic plan are an element of our long-term     strategy</td>
    </tr>
    <tr>
      <td>We may be unable to identify and complete <font color="blue">appropriate <font color="blue"><font color="blue">acquisition</font>s</font></font>     in a <font color="blue">timely manner</font> and no assurance can be provided that the <font color="blue">market price</font> of     potential business <font color="blue"><font color="blue"><font color="blue">acquisition</font>s</font> will</font> be acceptable</td>
    </tr>
    <tr>
      <td>In addition, many of our     <font color="blue">competitors</font> have greater financial <font color="blue">resources than</font> we have and may be willing     to pay more for these <font color="blue">businesses</font> or <font color="blue">selected assets</font></td>
    </tr>
    <tr>
      <td>Should we identify     <font color="blue">suitable <font color="blue">acquisition</font> targets</font>, we may be unable to complete <font color="blue"><font color="blue">acquisition</font>s</font> or     obtain  the  financing,  if <font color="blue">necessary</font>, for these <font color="blue"><font color="blue">acquisition</font>s</font> on terms     favorable to us</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue"><font color="blue">acquisition</font>s</font> pose a number of risks, including, <font color="blue">among others</font>,     that:                                         18       _________________________________________________________________    [54]Table of <font color="blue">Contents       </font>  –   we may not be able to <font color="blue">accurately</font> estimate the financial effect of     <font color="blue"><font color="blue">acquisition</font>s</font> on our business;       –   future <font color="blue"><font color="blue">acquisition</font>s</font> may require us to <font color="blue">issue capital stock</font> or spend     <font color="blue">significant</font> cash or may result in a decrease in our future operating income     or operating margins;       –   we may be unable to realize the anticipated benefits and synergies     from <font color="blue"><font color="blue">acquisition</font>s</font> as a result of <font color="blue">inherent risks</font> and <font color="blue">uncertainties</font>, including     <font color="blue">difficult</font>ies integrating acquired <font color="blue">businesses</font> or retaining their personnel,     partners, customers or other key <font color="blue">relationships</font> and risks that acquired     <font color="blue">entities may</font> not operate profitably or that <font color="blue"><font color="blue">acquisition</font>s</font> may not result in     improved operating performance; and       –   <font color="blue"><font color="blue">acquisition</font>s</font> may disrupt our business and distract our <font color="blue">management</font> from     other <font color="blue">responsibilities</font></td>
    </tr>
    <tr>
      <td>Our operating results may be <font color="blue">affected by current economic</font> and political     <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>The  continuing  events in the <font color="blue">Middle East </font>and concern for future     terrorist attacks, leave many economic and political <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">uncertainties</font> could adversely affect our business and revenues in the short     or long term in ways that <font color="blue">cannot presently</font> be predicted</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> on our ability to attract and retain our <font color="blue">management</font>     and staff</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> and scientific     staff,  including our chief executive officer, marketing, research and     <font color="blue">development</font>, technical support, technical service and <font color="blue">sales staff</font></td>
    </tr>
    <tr>
      <td>The loss     of services of key members of <font color="blue">management</font> <font color="blue">could delay</font> or reduce our product     <font color="blue">development</font>, marketing and sales and <font color="blue">technical support efforts</font></td>
    </tr>
    <tr>
      <td>In addition,     recruiting and retaining <font color="blue">qualified scientific</font> and other personnel to perform     research and <font color="blue">development</font>, technical support, technical service and marketing     and sales work will be critical to our success</td>
    </tr>
    <tr>
      <td>There is a shortage in our     industry of qualified <font color="blue">management</font> and <font color="blue">scientific personnel</font>, and <font color="blue">competition</font>     for these <font color="blue">individuals</font> is intense</td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be     able  to attract <font color="blue">additional</font> and retain existing personnel <font color="blue">necessary</font> to     achieve our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>The  trading  price of our <font color="blue">common stock</font> has been and is likely to     continue to be <font color="blue">highly volatile</font> and subject to wide <font color="blue">fluctuations</font> in price</td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> is in response to <font color="blue">various factors</font>, many of which are beyond     our control, including:     –   general economic <font color="blue">conditions</font> and <font color="blue">interest rates</font>;       –   <font color="blue">instability</font> in the <font color="blue">United States</font> and other financial markets and the     ongoing and <font color="blue">possible escalation</font> of unrest in the Middle East, other armed     <font color="blue">hostilities</font> or further acts or threats of terrorism in the <font color="blue">United States</font> or     elsewhere;       –   actual or anticipated <font color="blue">variations</font> in quarterly operating results from     historical results or estimates of results prepared <font color="blue">by securities analysts</font>;       –   <font color="blue">announcement</font>s of <font color="blue">technological</font> <font color="blue">innovations</font> or <font color="blue">new products</font> or services     by us or our <font color="blue">competitors</font>;       –   changes in financial estimates <font color="blue">by securities analysts</font>;       –     <font color="blue">conditions</font>  or  trends  in  the  life science, bio<font color="blue">technology</font> and     <font color="blue">pharmaceutical</font> <font color="blue">industries</font>;       –   <font color="blue">announcement</font>s by us of <font color="blue">significant</font> <font color="blue"><font color="blue">acquisition</font>s</font>, <font color="blue">strategic partners</font>hips,     joint ventures or capital <font color="blue">commitment</font>s;       –   <font color="blue">additions</font> or <font color="blue">departures</font> of key personnel;       –   sales of our <font color="blue">common stock</font>; and       –   the potential adverse impact of the <font color="blue">secondary trading</font> of our stock on     <font color="blue">foreign exchanges which</font> are subject to less <font color="blue">regulatory</font> oversight than The     Nasdaq National Market, without our <font color="blue">permission</font>, and the activity of the     <font color="blue">market makers</font> of our <font color="blue">stock on such exchanges</font>, including the risk that such     <font color="blue">market makers</font> may engage in naked short                                         19       _________________________________________________________________    [55]Table of <font color="blue">Contents       </font>    sales and/or other <font color="blue">deceptive trading practices which may artificially</font>     depress or <font color="blue">otherwise affect</font> the price of our <font color="blue">common stock</font> on The Nasdaq     National Market</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general, and <font color="blue">The Nasdaq Stock Market     </font>and the market for <font color="blue">technology</font> companies in particular, has experienced     <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font> that have often been unrelated or     <font color="blue">disproportionate</font> to the operating performance of those companies</td>
    </tr>
    <tr>
      <td>Further,     there has been particular <font color="blue">volatility</font> in the <font color="blue">market price</font>s of securities of     life  sciences  companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and <font color="blue">industry factors may</font>     <font color="blue">seriously harm</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>, regardless of our     operating performance</td>
    </tr>
    <tr>
      <td>In the past, following periods of <font color="blue">volatility</font> in the     <font color="blue">market price</font> of a company’s securities, securities class action <font color="blue">litigation</font>     has <font color="blue">often been instituted</font></td>
    </tr>
    <tr>
      <td>A securities class action suit <font color="blue">against us</font> could     result in substantial costs, <font color="blue">potential liabilities</font> and the diversion of     <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">certificate</font> of incorporation, bylaws and     stockholder  rights  plan  and  <font color="blue"><font color="blue">Delaware </font> </font>law could make a <font color="blue">third party</font>     <font color="blue">acquisition</font> of us <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of incorporation, bylaws and <font color="blue">stockholder rights</font> plan     <font color="blue">contain provisions</font> that could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to     acquire us, even if doing so would be <font color="blue">beneficial</font> to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We are     also subject to <font color="blue">certain provisions</font> of <font color="blue">Delaware </font>law that <font color="blue">could delay</font>, deter     or prevent a change in control of us</td>
    </tr>
    <tr>
      <td>These provisions <font color="blue">could limit</font> the price     that investors might be willing to pay in the future for shares of our     <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>